LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists-Pipeline Insights, 2017

LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists-Pipeline Insights

Wiseguyreports.Com Adds “LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists-Pipeline Insights Market -Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2022” To Its Research Database.

Get Sample Report @
https://www.wiseguyreports.com/sample-request/476533-lag-3-antagonists-tim-3-antagonists-ox40-agonists-pipeline-insights-2016

Covered In This Report:
DelveInsight’s, “LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists-Pipeline Insights, 2016”, report provides comprehensive insight and understanding for all the pipeline drugs that fall under LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. With the emerging immune-oncology therapeutic strategy for T-cell-mediated diseases, companies are focusing on the development of immune-check inhibitors like Lag-3, OX-40 and TIM-3 inhibitors which gained importance in recent years.
Report highlights that majorly development is seen for Lag-3 antagonist, with the lead drug of Prima BioMed in Phase II stage of development. In case of OX-40 agonists close to 4 drugs are in Phase I stage of development with AstraZeneca having its 2 drug candidates in Phase I. Majorly drug candidates are seen in early stages of development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists.
The Report gives insights on 33+ products with 20+ different technologies. The Report also provides LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists related therapeutic assessments by molecule type, route of administration, monotherapy and combination products.
Scope
• DelveInsight’s report provides a LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Landscape across the globe
• The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
• Coverage of the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists and also provide company profiling
• Pipeline products coverage based on various stages of development from NDA filings to discovery.
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reason to Buy

 Complete Pipeline intelligence and complete understanding over therapeutics development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists
 Identify different type of technologies involved in the development of the therapeutics.
 Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
 Track your competitors and develop strategic initiatives to support your drug development activities.
 Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
 Devise corrective measures for pipeline projects by understanding LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline in-depth
 Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
Make An Enquiry Before Buying This Report@
https://www.wiseguyreports.com/enquiry/476533-lag-3-antagonists-tim-3-antagonists-ox40-agonists-pipeline-insights-2016
Table of contents:
LAG-3, TIM-3 & OX40 Overview
Total Products Overview
Products Share by Clinical Stages
Products Share by Pre-clinical and Discovery Stages
LAG-3 Antagonists
Pipeline Therapeutics
Therapeutics under Development by Companies
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis

Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
TIM-3 Antagonists
Pipeline Therapeutics
Therapeutics under Development by Companies
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
OX40 Agonists
Pipeline Therapeutics
Therapeutics under Development by Companies
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Additional Information
Discontinued Products
Companies Involved in Therapeutics Development
Methodology
Consulting Services
About DelveInsight
Contact Us
Disclaimer

List of tables
Table 1: Total Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists, 2016
Table 2: Share of Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists in Clinical Stages, 2016
Table 3: Share of Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists in Pre-clinical and Discovery, 2016
Table 4: Number of Products under Development for LAG-3 Antagonists, 2016
Table 5: Number of Products under Development by Companies, 2016
Table 6: Mid Stage Products (Phase II), 2016
Table 7: Early Stage Products (Phase I and IND), 2016
Table 8: Discovery and Pre-clinical Stage Products, 2016
Table 9: Assessment by Monotherapy Products for LAG-3 Antagonists, 2016
Table 10: Assessment by Combination Products for LAG-3 Antagonists, 2016
Table 11: Assessment by Route of Administration for LAG-3 Antagonists, 2016
Table 12: Assessment by Stage and Route of Administration for LAG-3 Antagonists, 2016
Table 13: Assessment by Molecule Type for LAG-3 Antagonists, 2016
Table 14: Assessment by Stage and Molecule Type for LAG-3 Antagonists, 2016
Table 15: Number of Products under Development for TIM-3 Antagonists, 2016
Table 16: Number of Products under Development by Companies, 2016
Table 17: Early Stage Products (Phase I and IND), 2016
Table 18: Discovery and Pre-clinical Stage Products, 2016
Table 19: Assessment by Monotherapy Products for TIM-3 Antagonists, 2016
Table 20: Assessment by Route of Administration for TIM-3 Antagonists, 2016
Table 21: Assessment by Stage and Route of Administration for LAG-3 Antagonists, 2016
Table 22: Assessment by Molecule Type for TIM-3 Antagonists, 2016
Table 23: Assessment by Stage and Molecule Type for TIM-3 Antagonists, 2016
Table 24: Number of Products under Development for OX40 Agonists, 2016
Table 25: Number of Products under Development by Companies, 2016
Table 26: Early Stage Products (Phase I and IND), 2016
Table 27: Discovery and Pre-clinical Stage Products, 2016
Table 28: Assessment by Monotherapy Products for OX40 Agonists, 2016
Table 29: Assessment by Route of Administration for OX40 Agonists, 2016
Table 30: Assessment by Stage and Route of Administration for OX40 Agonists, 2016
Table 31: Assessment by Molecule Type for OX40 Agonists, 2016
Table 32: Assessment by Stage and Molecule Type for OX40 Agonists, 2016
Table 33: Discontinued Products, 2016
Table 34: Companies Involved in Therapeutic Development, 2016
List of figures:
Figure 1: Total Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists, 2016 (%)
Figure 2: Share of Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists in Clinical Stages, 2016 (%)
Figure 3: Share of Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists in Pre-clinical and Discovery, 2016 (%)
Figure 4: Number of Products under Development for LAG-3 Antagonists, 2016
Figure 5: Mid Stage Products (Phase II), 2016
Figure 6: Early Stage Products (Phase I and IND), 2016
Figure 7: Discovery and Pre-clinical Stage Products, 2016
Figure 8: Assessment by Monotherapy Products for LAG-3 Antagonists, 2016
Figure 9: Assessment by Combination Products for LAG-3 Antagonists, 2016
Figure 10: Assessment by Route of Administration for LAG-3 Antagonists, 2016
Figure 11: Assessment by Stage and Route of Administration for LAG-3 Antagonists, 2016
Figure 12: Assessment by Molecule Type for LAG-3 Antagonists, 2016
Figure 13: Assessment by Stage and Molecule Type for LAG-3 Antagonists, 2016
Figure 14: Number of Products under Development for TIM-3 Antagonists, 2016
Figure 15: Early Stage Products (Phase I and IND), 2016
Figure 16: Discovery and Pre-clinical Stage Products, 2016
Figure 17: Assessment by Monotherapy Products for TIM-3 Antagonists, 2016
Figure 18: Assessment by Combination Products for TIM-3 Antagonists, 2016
Figure 19: Assessment by Route of Administration for TIM-3 Antagonists, 2016
Figure 20: Assessment by Stage and Route of Administration for TIM-3 Antagonists, 2016
Figure 21: Assessment by Molecule Type for TIM-3 Antagonists, 2016
Figure 22: Assessment by Stage and Molecule Type for TIM-3 Antagonists, 2016
Figure 23: Number of Products under Development for OX-40 Agonists, 2016
Figure 24: Early Stage Products (Phase I and IND), 2016
Figure 25: Discovery and Pre-clinical Stage Products, 2016
Figure 26: Assessment by Monotherapy Products for OX40 Agonists, 2016
Figure 27: Assessment by Route of Administration for OX40 Agonists, 2016
Figure 28: Assessment by Stage and Route of Administration for OX40 Agonists, 2016
Figure 29: Assessment by Molecule Type for OX40 Agonists, 2016
Figure 30: Assessment by Stage and Molecule Type for OX40 Agonists, 2016
Continued...
Buy Now @
https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=476533
Contact Us:
Norah Trent
Partner Relations & Marketing Manager
Sales@Wiseguyreports.Com
Ph: +1-646-845-9349 (Us)
Ph: +44 208 133 9349 (Uk)

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

WISE GUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar
Pune - 411028
Maharashtra, India

This release was published on openPR.